[Interpretation of the Chinese expert consensus on the diagnosis and treatment of polycythemia vera(2016)].
作者信息
Shi Z X, Xiao Z J
机构信息
Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, CAMS & PUMC, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):852-857. doi: 10.3760/cma.j.issn.0253-2727.2016.10.005.
Abstract
摘要
相似文献
1
[Interpretation of the Chinese expert consensus on the diagnosis and treatment of polycythemia vera(2016)].《真性红细胞增多症诊断与治疗中国专家共识（2016年版）》解读
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):852-857. doi: 10.3760/cma.j.issn.0253-2727.2016.10.005.
2
[Chinese expert consensus on the diagnosis and treatment of polycythemia vera (2016)].真性红细胞增多症诊断与治疗中国专家共识（2016年版）
Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):265-8. doi: 10.3760/cma.j.issn.0253-2727.2016.04.001.
3
[Chinese expert consensus on the comprehensive management of thromboembolism in polycythemia vera].真性红细胞增多症血栓栓塞综合管理中国专家共识
Zhonghua Yi Xue Za Zhi. 2023 Feb 7;103(5):319-328. doi: 10.3760/cma.j.cn112137-20220708-01508.
4
Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania.利用分子检测来识别宾夕法尼亚州东部真性红细胞增多症患者群。
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):534-40. doi: 10.1158/1055-9965.EPI-08-0922. Epub 2009 Feb 3.
5
Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera.走出古老模式：真性红细胞增多症新兴治疗药物的最新进展
Expert Opin Emerg Drugs. 2021 Sep;26(3):209-218. doi: 10.1080/14728214.2021.1945579. Epub 2021 Jun 30.
6
The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns.真性红细胞增多症研究组时代以来真性红细胞增多症的诊断与管理：美国血液学会成员实践模式调查
Blood. 2002 Feb 15;99(4):1144-9. doi: 10.1182/blood.v99.4.1144.
7
[Chinese guideline for the diagnosis and treatment of polycythemia vera (2022)].[真性红细胞增多症诊断与治疗中国指南（2022年版）]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jul 14;43(7):537-541. doi: 10.3760/cma.j.issn.0253-2727.2022.07.002.
8
Polycythemia vera: a retrospective and reprise.真性红细胞增多症：回顾与重述
J Lab Clin Med. 1997 Oct;130(4):365-73. doi: 10.1016/s0022-2143(97)90035-4.
9
POLYCYTHEMIA VERA: PERIPHERAL VASCULAR MANIFESTATIONS.真性红细胞增多症：外周血管表现
Calif Med. 1964 Feb;100(2):92-6.
引用本文的文献
1
The Predictive Value of Neutrophil-Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events.中性粒细胞-淋巴细胞比值对初诊时血栓事件的预测价值。
Biomed Res Int. 2022 Aug 8;2022:9343951. doi: 10.1155/2022/9343951. eCollection 2022.
本文引用的文献
1
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
2
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.世界卫生组织真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化诊断标准的修订理由及拟议更改
Blood Cancer J. 2015 Aug 14;5(8):e337. doi: 10.1038/bcj.2015.64.
3
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.聚乙二醇干扰素α-2b，一种新型的干扰素α-2b，在真性红细胞增多症患者中诱导出高缓解率且毒性低。
Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.
4
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.盐酸阿那格雷和芦可替尼治疗真性红细胞增多症。
Expert Opin Pharmacother. 2015 Jun;16(8):1185-94. doi: 10.1517/14656566.2015.1036029. Epub 2015 Apr 14.
5
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.芦可替尼与标准疗法治疗真性红细胞增多症的对比
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
6
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895.
7
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.聚乙二醇化脯氨酸干扰素α-2b治疗真性红细胞增多症患者的分子反应和染色体畸变
Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2.
8
Presence of calreticulin mutations in JAK2-negative polycythemia vera.CALR 突变在 JAK2 阴性真性红细胞增多症中的存在。
Blood. 2014 Dec 18;124(26):3964-6. doi: 10.1182/blood-2014-06-583161. Epub 2014 Oct 10.
9
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.治疗强度较低可能是隐匿性真性红细胞增多症年轻患者血栓形成风险增加的原因。
Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16.
10
The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.血清促红细胞生成素水平及JAK2 V617F等位基因负荷在真性红细胞增多症诊断中的作用。
Br J Haematol. 2014 Nov;167(3):411-7. doi: 10.1111/bjh.13047. Epub 2014 Jul 18.
Zotero 插件